Details der Publikation - Role of butyrogenic Firmicutes in type-2 diabetes

Role of butyrogenic Firmicutes in type-2 diabetes

Objective The aim of this review is to speculate the pre-clinical and clinical evidences indicating the association between butyrate-synthesizing firmicutes and development and progression of type 2 diabetes mellitus. Methodology Literature was searched using ‘Google Scholar’ and ‘PubMed’ to find out most relevant articles for the scope of this review. Information was also gathered from authentic sources such as the World Health Organisation and the International Diabetes Federation. Results Evidences suggest that an abnormal perturbation in the gut microbiome characterized by subsided levels of butyrate-producing bacteria may gradually result in the progression of type-2 diabetes; however, the explicit mechanisms underlying and implicating the role of specific butyrate-producing microbes remain unclear. Conclusions This review explicitly summarizes the role of butyrate-synthesizing firmicutes known to be reduced in the subjects with type-2 diabetes mellitus in host metabolic health and contemplates the putative and reported mechanisms underlying its implication in the pathophysiology of type-2 diabetes mellitus..

Medienart:	E-Artikel

Erscheinungsjahr:	2022
Erschienen:	2022

Enthalten in:	Zur Gesamtaufnahme - volume:21
Enthalten in:	Journal of diabetes & metabolic disorders - 21(2022), 2 vom: 14. Juli, Seite 1873-1882

Sprache:	Englisch

Beteiligte Personen:	James, Meenu Mariya [VerfasserIn] Pal, Namrata [VerfasserIn] Sharma, Poonam [VerfasserIn] Kumawat, Manoj [VerfasserIn] Shubham, Swasti [VerfasserIn] Verma, Vinod [VerfasserIn] Tiwari, Rajnarayan R [VerfasserIn] Singh, Birbal [VerfasserIn] Nagpal, Ravinder [VerfasserIn] Sarma, Devojit Kumar [VerfasserIn] Kumar, Manoj [VerfasserIn]

Links:	Volltext [lizenzpflichtig]

Themen:	Butyrate Butyric acid Diabetes Firmicutes Gut Microbiota Microflora

Anmerkungen:	© The Author(s), under exclusive licence to Tehran University of Medical Sciences 2022

doi:	10.1007/s40200-022-01081-5

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC2132777241

Internformat


LEADER	01000caa a22002652 4500
001	OLC2132777241
003	DE-627
005	20240408161823.0
007	cr uuu---uuuuu
008	230506s2022 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s40200-022-01081-5 \|2 doi
035			\|a (DE-627)OLC2132777241
035			\|a (DE-He213)s40200-022-01081-5-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q VZ
100	1		\|a James, Meenu Mariya \|e verfasserin \|4 aut
245	1	0	\|a Role of butyrogenic Firmicutes in type-2 diabetes
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © The Author(s), under exclusive licence to Tehran University of Medical Sciences 2022
520			\|a Objective The aim of this review is to speculate the pre-clinical and clinical evidences indicating the association between butyrate-synthesizing firmicutes and development and progression of type 2 diabetes mellitus. Methodology Literature was searched using ‘Google Scholar’ and ‘PubMed’ to find out most relevant articles for the scope of this review. Information was also gathered from authentic sources such as the World Health Organisation and the International Diabetes Federation. Results Evidences suggest that an abnormal perturbation in the gut microbiome characterized by subsided levels of butyrate-producing bacteria may gradually result in the progression of type-2 diabetes; however, the explicit mechanisms underlying and implicating the role of specific butyrate-producing microbes remain unclear. Conclusions This review explicitly summarizes the role of butyrate-synthesizing firmicutes known to be reduced in the subjects with type-2 diabetes mellitus in host metabolic health and contemplates the putative and reported mechanisms underlying its implication in the pathophysiology of type-2 diabetes mellitus.
650		4	\|a Butyrate
650		4	\|a Butyric acid
650		4	\|a Diabetes
650		4	\|a Gut
650		4	\|a Microbiota
650		4	\|a Microflora
650		4	\|a Firmicutes
700	1		\|a Pal, Namrata \|4 aut
700	1		\|a Sharma, Poonam \|4 aut
700	1		\|a Kumawat, Manoj \|4 aut
700	1		\|a Shubham, Swasti \|4 aut
700	1		\|a Verma, Vinod \|4 aut
700	1		\|a Tiwari, Rajnarayan R \|4 aut
700	1		\|a Singh, Birbal \|4 aut
700	1		\|a Nagpal, Ravinder \|4 aut
700	1		\|a Sarma, Devojit Kumar \|4 aut
700	1		\|a Kumar, Manoj \|4 aut
773	0	8	\|i Enthalten in \|t Journal of diabetes & metabolic disorders \|d Springer International Publishing, 2012 \|g 21(2022), 2 vom: 14. Juli, Seite 1873-1882 \|h Online-Ressource \|w (DE-627)723900051 \|w (DE-600)2680289-2 \|w (DE-576)370708245 \|x 2251-6581 \|7 nnns
773	1	8	\|g volume:21 \|g year:2022 \|g number:2 \|g day:14 \|g month:07 \|g pages:1873-1882
856	4	0	\|u https://dx.doi.org/10.1007/s40200-022-01081-5 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_250
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2050
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2472
912			\|a GBV_ILN_2474
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4328
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 21 \|j 2022 \|e 2 \|b 14 \|c 07 \|h 1873-1882

Role of butyrogenic Firmicutes in type-2 diabetes

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände